NasdaqGS - Delayed Quote USD

Syndax Pharmaceuticals, Inc. (SNDX)

Compare
19.75 -0.07 (-0.35%)
At close: October 15 at 4:00 PM EDT
Currency in USD All numbers in thousands
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
3,500.00
--
--
139,709.00
1,517.00
--
Operating Expense
291,490.00
229,954.00
151,757.00
113,489.00
72,940.00
--
Operating Income
-287,990.00
-229,954.00
-151,757.00
26,220.00
-71,423.00
--
Net Non Operating Interest Income Expense
24,202.00
20,955.00
2,735.00
-1,496.00
-1,516.00
--
Other Income Expense
-294.00
-361.00
-316.00
202.00
-219.00
--
Pretax Income
-264,082.00
-209,360.00
-149,338.00
24,926.00
-73,158.00
--
Net Income Common Stockholders
-264,082.00
-209,360.00
-149,338.00
24,926.00
-77,064.00
--
Diluted NI Available to Com Stockholders
-264,082.00
-209,360.00
-149,338.00
24,926.00
-77,064.00
--
Basic EPS
-3.40
-2.98
-2.46
0.48
-1.87
--
Diluted EPS
-3.40
-2.98
-2.46
0.48
-1.87
--
Basic Average Shares
78,222.92
70,370.52
60,760.91
52,064.81
41,308.24
--
Diluted Average Shares
78,222.92
70,370.52
60,760.91
52,064.81
41,308.24
--
Total Operating Income as Reported
-287,990.00
-229,954.00
-151,757.00
26,220.00
-71,423.00
--
Total Expenses
291,490.00
229,954.00
151,757.00
113,489.00
72,940.00
--
Net Income from Continuing & Discontinued Operation
-264,082.00
-209,360.00
-149,338.00
24,926.00
-73,158.00
--
Normalized Income
-264,082.00
-209,360.00
-149,338.00
24,926.00
-73,158.00
--
Interest Income
24,435.00
21,163.00
5,872.00
403.00
841.00
--
Interest Expense
233.00
208.00
3,137.00
1,899.00
2,357.00
--
Net Interest Income
24,202.00
20,955.00
2,735.00
-1,496.00
-1,516.00
--
EBIT
-263,849.00
-209,152.00
-146,201.00
26,825.00
-70,801.00
--
EBITDA
-263,837.00
-209,140.00
-146,168.00
26,868.00
-70,712.00
--
Reconciled Depreciation
12.00
12.00
33.00
43.00
89.00
--
Net Income from Continuing Operation Net Minority Interest
-264,082.00
-209,360.00
-149,338.00
24,926.00
-73,158.00
--
Normalized EBITDA
-263,837.00
-209,140.00
-146,168.00
26,868.00
-70,712.00
--
12/31/2019 - 3/2/2016

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers